Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system
{{output}}
Background: Cardiovascular adverse events represent critical complications of antineoplastic therapy with profound implications for cancer survivorship and treatment outcomes. Despite the clinical significance, comprehensive phar... ...
